Combination therapy for advanced or metastatic non-small cell lung cancer will be tested in new clinical trial
Lung cancer metastasis. The NCI’s Center for Cancer Research has opened a clinical trial of a new combination treatment for patients with advanced or metastatic NSCLC that cannot be treated surgically.
Non-small cell lung cancer (NSCLC) develops when abnormal lung cells begin to grow out of control. These cells can form into a tumor and spread to other areas of the body. David Schrump, M.D., of the Thoracic Epigenetics Section of the Thoracic and Gastrointestinal Oncology Branch is leading a clinical trial of a new combination treatment for patients with advanced or metastatic NSCLC that cannot be treated surgically. In this trial, patients will be treated with an immune checkpoint inhibitor, pembrolizumab, that blocks a protective mechanism on cancer cells allowing the immune system to target and kill those cells. In addition to pembrolizumab, patients will also receive two epigenetic drugs - decitabine and tetrahydrouridine. These drugs affect the way genes switch on and off within cells and can inhibit abnormal cell growth.
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow by treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland. Search all CCR clinical trials, and subscribe to have the latest CCR clinical trials sent to your inbox.Summary Posted: 11/2017